
United States · Information technology & services startup
Nanome is a San Diego-based enterprise software company founded in 2015 by engineering students from the University of California, San Diego.
Funding reportedLast round: Series A
Nanome is a San Diego-based enterprise software company founded in 2015 by engineering students from the University of California, San Diego.
The company focuses on providing an AI-assisted scientific copilot and a multi-user spatial computing platform aimed at accelerating drug discovery and molecular visualization. Its core mission is to serve as the ultimate interface for scientific discovery, enabling top R&D labs to conduct advanced research and make informed decisions. The Nanome platform offers a collaborative workspace for drug discovery, allowing scientists to visualize, modify, and simulate proteins, chemical compounds, and nucleic acids in real-time. It features specialized AI agents for tasks such as docking and antibody design. The software is available on various platforms, including Meta Quest Pro and SteamVR, and integrates with existing computational tools used by R&D teams. Nanome also emphasizes accessibility, catering to a wide range of users, from pharmaceutical companies and biotech firms to students and amateur scientists, facilitating a collaborative environment for learning and research.
Funding, as reported
What they build
Known for
health caremolecular structuresprotein analysisdrug development in vrmolecular modelingxr for structural biologymolecular visualizationvirtual reality educationvirtual reality protein analysisxr pluginsxr-based educationeducationinformation technology & servicesmolecular docking toolsmolecular simulationxr hardware support
Built with from their website
Google Tag ManagerGoogle CloudStripe PaymentsYouTubeGoogle WorkspaceCloudFlareViewport MetaCSSHubspotGoogle Cloud Hosting
Google MeetCloudFlare CDNPriority HintsJavaScriptCloudflare InsightsNuxtjsMobile FriendlyBootstrap
Add your raise, your deck and your story, and put Nanome in front of investors. Or tell us what we have wrong.